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Abstract: Radioiodine-131 (I-131) is used in treatment of benign thyroid diseases with hyperthyroidism; toxic diffuse 
goiter, toxic nodular goiter and toxic multinodular goiter for long years. Treatment success depends on various factors. 
The most important factor affecting the success of treatment is the susceptibility to target tissue I-131. This review aims 
to give information about the physical and biological characteristics of I-131, advantages and disadvantages, indications 
and contraindications for I-131 therapy, patient preperation and administiration of I-131, dose selection, precautions on 
possible side effects, evaluation of treatment response and make an overview on the clinical studies about I-131 therapy.  
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INTRODUCTION 
Radioiodine-131 (I-131) is used in treatment of 
benign thyroid diseases with hyperthyroidism; toxic 
diffuse goiter (Graves disease), toxic nodular goiter 
(toxic adenoma) and toxic multinodular goiter for 
several years as well as non toxic diffuse goiter, non 
toxic adenoma and non toxic multinodular goiter. 
Advantages of this treatment are good tolerability, easy 
application, safety and efficacy. The critical organ is 
thyroid gland. I-131 is taken up by follicular cells. 
Retention of I-131 in the cells depends on the 
metabolic activity of the cells. Radioiodine-131 emits 
beta minus (β-) used for therapy. Due to the 
penetration of beta particles in tissue, damaging effect 
of β- radiation is limited to thyroid cells. The physical 
and biological characteristics of I-131, advantages and 
disadvantages, indications and contraindications for I-
131 therapy, patient preperation and administiration of 
I-131, dose selection, precautions on possible side 
effects, evaluation of treatment response and an 
overview on the clinical studies about I-131 therapy in 
benign thyroid diseases are presented under this title.  
RADIOPHARMACEUTICAL 
Physical Characteristics 
Iodine-131 Sodium iodide (NaI) is a 
radiopharmaceutical obtained by Uranium (235U) 
fission or by means of neutron bombardment. High 
gamma energy (364 keV) is used for diagnostic 
purposes, high beta energy (610 keV) for ablation and 
therapy. Beta radiation destroy the cells within 0.5-2 
mm distance from the center. Radioiodine has capsule 
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and liquid forms for oral administration. The capsule is 
prepared by evaporating a no carrier added (NCA) I-
131 NaI alcohol solution to the inner surface of the 
gelatin capsule. I-131 in the isotonic saline solution is 
clear and colorless. The pH value is between 7.5 and 
9. The physical half-life is 8.1 days. Shelf life is 4 
weeks after calibration [1]. 
Pharmacokinetics and Pharmacodynamics 
Radioiodine is absorbed from the intestines after 
oral intake and reaches a maximum blood level within 3 
hours. Approximately 90% of the administered dose is 
excreted from the kidneys, while 10% is excreted in 
faeces and sweat. The urinary excretion is about 50% 
after 24 hours of application [2]. High-energy β-particle 
radiation causes damage to thyroid tissue. The 
penetration of β- radiation is about 0.8 mm on average. 
By the radiation exposure of thyroid follicle cells, cell 
necrosis and DNA damage occurs in surviving cells. 
This results in inflammation and subsequent fibrosis. 
Thus, synthesis capacity of the thyroid gland decreases 
[3-8]. 
Advantages And Disadvantages 
The first radioactive iodine treatment in benign 
thyroid diseases was performed in the USA in 1941 [9]. 
It is used in Europe since 1950s [10].  
As with any treatment modality, radioiodine 
treatment has advantages and disadvantages. 
Advantages are; It is cheap and effective (because it is 
selective and destructive in the target cell), easy to 
apply, reliable, and avoids possible complications of 
surgery. Disadvantages are; Hypothyroidism, the need 
for lifelong medication, slow hyperthyroidism therapy, 
the possibility of recurrence after initial treatment, the 
need for repeat treatment and development and/or 
worsening of ophthalmoplegia [7, 11]. 
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Indications 
Indications include thyroid diseases with 
hyperthyroidism are classified as; Toxic diffuse goiter 
(Graves disease), toxic nodular goiter (toxic adenoma) 
and toxic multinodular goiter, non toxic diffuse goiter, 
non toxic adenoma and non toxic multinodular goiter 
[12, 13]. Small and medium-sized thyroid gland, 
patients with recurrence after medication and surgical 
treatment, cases where medication and surgery are 
contraindicated, patients over 40 years of age and 
cases with high risk of surgery are preferred. 
Toxic Diffuse Goiter (Graves' Disease) 
Graves' disease is the most common cause of 
hyperthyroidism, and 70-80% of patients presenting 
with thyrotoxicosis have Graves' disease etiology. The 
disease shows a peak in the fourth and fifth decades 
with the occurrence in all age groups. It is five times 
more common in females than in males. Thyroid-
stimulating immunoglobulins similar to TSH bind to the 
follicular cells causing hyperplasia and autonomous 
thyroid hyperfunction [14]. 
The diagnosis of Graves' disease is often simple. 
Thyrotoxicosis, diffuse goitre without nodule and 
characteristic ophthalmopathia and presence of 
pretibial dermopathy are of clinical value. However, in 
some patients the diagnosis is doubtful and not certain 
[14]. 
If surgery or medical treatment is contraindicated in 
patients with Graves' disease, radioactive iodine 
treatment in elderly patients with the consent of the 
patient is the first treatment option.  
For patients who do not take regular medications 
(drug interactions, leukopenia, liver function deteriora- 
tion) and in patients where long-term antithyroid drug 
treatment is not appropriate (due to the need for fewer 
visits to the doctor and antithyroid medication is not 
successful) or where side effects are observed and if 
hyperthyroidism persists despite 12-18 months of 
treatment, radioiodine is indicated. 
Graves' disease heals with this treatment except for 
very few cases. The duration of the effect depends on 
the applied doses. Cure occurs in most patients. In 
patients who are not cured, the severity of symptoms 
decreases. Treatment is repeated if the disease 
continued despite treatment (6 months to 1 year later, 
recurrent or 25% overdose). Approximately 10% of 
patients necessitate a second dose. Cure is achieved 
in 10-40% of Graves' patients who received a second 
dose [15]. 
Graves Ophthalmopathy and Radioactive Iodine 
Treatment in Smoking 
There is a high risk of developing graves 
ophthalmopathy in smokers after radioactive iodine 
treatment, especially in male sex. Patients with inactive 
ophthalmopathy can also receive radioactive iodine 
without steroids. Patients who smoke, who have 
positive thyroid receptor antibodies (TRAb) and clinical 
activity score (CAS) >1 should be reevaluated for 
radioiodine therapy. In patients who smoke and don’t 
have graves ophthalmopathy, ophthalmopathy may 
occur after radioiodine therapy. Prophylactic steroid 
administration is not routinely recommended if smoking 
patients don’t have graves ophthalmopathy. If smoking 
patients with graves ophthalmopathy are treated with 
radioiodine therapy, ophthalmopathy may worsen  
[16, 17].  
Toxic Solitary Nodular Goiter (Toxic Adenoma, 
Autonomous Toxic Nodule) 
Hyper functioning thyroid nodules are the second 
most common cause of hyperthyroidism. It is usually 
seen after fifth decade and is often associated with 
cardiovascular symptoms. They do not show immuno- 
logic, ophthalmologic and dermatological changes 
while they present with thyrotoxic symptoms and signs 
similar to Graves' disease [18]. Despite surgery is an 
option in treatment, radioiodine therapy is often 
preferred [14, 19, 20]. Thyroid cancer should be ruled 
out for radioiodine therapy. 
Toxic Multinodular Goiter (Plummer’s Disease) 
Toxic multinodular goiter is often seen in older age 
group. This disease is associated with tachyarrhythmia, 
weight loss, depression, anxiety and insomnia. 
Radioiodine therapy may be preferred, especially in 
patients with no pressure symptoms [21]. Thyroid 
cancer should be ruled out before radioiodine therapy. 
Non Toxic Diffuse/Nodular/Multinodular Goiter 
In the presence of large and symptomatic goiters 
without thyrotoxicosis, especially if there is a high risk 
of surgery, intentional radiotherapy may be considered 
to reduce the size of the thyroid gland. Prior to non-
toxic goiter therapy, rhs TSH can be stimulated to 
increase iodine uptake and improve the efficacy of 
treatment [13]. Improved I-131 uptake by rhTSH 
stimulation and administration of a radioiodine dose of 
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30 mCi in non-toxic multinodular goiter resulted in 
better results, such as a 34% reduction in basal volume 
[22]. There are no significant side effects detected after 
rhTSH administered 24 hours before treatment 
compared to treatment without rhTSH stimulation [16].  
Absolute Contraindications 
Pregnancy is an absolute contraindication. The 
radioiodine pass freely through the placenta. The fetal 
thyroid concentrates iodine after 10-12 weeks. Thus, 
severe hypothyroidism occurs with damage to the 
thyroid gland. Maternal bladder activity also causes 
fetal irradiation. The presence of accompanying thyroid 
cancer is another contraindication. It is recommended 
that women who receive treatment are not conceived 
for at least 6 months (usually 1 year). Male patients 
who are treated with radioiodine are advised not to be 
fathers for at least 4 months (usually 6 months)  
[11, 15, 21]. 
Relative Contraindications  
Uncontrolled urinary incontinence (patient should be 
catheterized), renal insufficiency, active advanced 
ophthalmopathy (especially in patients with cigarette 
smoking) are relative contraindicaitons. In mild and 
moderate ophthalmopathy, radioiodine can be given 
with steroids, but it is often not recommended in severe 
ophthalmopathy as it may lead to worsening of 
ophthalmopathy. Under 15 years of age it is 
increasingly used although it is still a matter of debate 
[11, 21, 23, 24].  
Even in patients with known iodine susceptibility, 
radioiodine therapy is not contraindicated. Since the 
elemental iodine content of I-131 preparations is as low 
as 0.05-0.18 µg, the hypersensitivity reaction is unlikely 
to occur in these patients [21]. 
Patient Preperation 
Low iodine diet is administered for 2 weeks before 
treatment (Table 1). For better absorption of 
radioiodine, fasting is important for 4-6 hours before 
oral administration. In order to prevent nausea and 
vomiting, it is advised not to take solid food for 2 hours 
and liquids for 1 hour after treatment. Drugs and/or 
substances affecting iodine involvement in the 
functional of the thyroid gland should be discontinued 
at given times (Table 2). Written and verbal information 
about radiation protection should be given before 
treatment. Women should be tested for pregnancy 
during the fertility period. 
Patients with heart failure and uncontrolled atrial 
fibrillation should be treated with appropriate diuretics 
and antiarrhythmics (excluding amiodarone) as well as 
medical antithyroid treatments. Βeta blockers 
(propranol 20-40 mg) may be used in symptomatic 
patients (tachycardia, tremor). Βeta blockers should be 
started before radioiodine therapy and should continue 
until clinical findings disappear after treatment [25, 26].  
Table 1: Avoided Food 
Iodized salt 
Milk and derivatives (cheese, yoghurt, ice-cream etc. 
Seafood 
Processed meat products (salami, sausage etc.) 
Packed food (chips, cookies, biscuits etc) 
Canned vegetables and fruits 
Greean vegetables (spinach, lettuce etc) 
Red pepper 
Red food dye 
 
Table 2: Drugs Decreasing Radioidine uptake in Thyroid 
Cells and Recommended Withdrawal Time  
Drug or Molecule Recommended Withdrawal Time 
Propylthiouracil, perchlorate, 
sulfonamides, tapazole, thiocyanate, 
penicillin, nitrates, antihistamines, 
anticoagulants  
1 week 
Iodine containing solutions 
(Lugolsolution, betadin), antitussives 
and vitamin preparates 
Triiodothyronin (T3) 
2 weeks 
Tetraiodothyronin (T4) 4-6 weeks 
Amiodarone 4-12 weeks 
i.v. contrast agents 1-3 weeks 
Oral cholecystographic agents 2-3 weeks 
 
Administration 
Radioactive iodine is administered peroral (capsule 
or solution) or intravenously. During the first 24-48 
hours the patient is recommended to chew gums or 
drink lemon juice to increase salivation. If the patient is 
still thyrotoxic at 3-6 months (often 6 months) after 
treatment, second treatment may be applied. Increased 
dosed by at least 25%of the first dose is 
recommended, rarely repeated doses are needed  
[11, 21]. 
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Dose Selection 
The effectiveness of radioiodine therapy is related 
to the size of the thyroid gland, radioactive iodine 
uptake (RAIU) value, and I-131 metabolism [7, 29]. The 
target tissue mass and the dose administered are the 
two most important factors in the efficacy of the 
treatment [29, 30]. Some researchers have reported 
that the most important factors determining treatment 
efficacy are gland size and serum free triiodothyronine 
(FT3) concentration before treatment [31]. Studies on 
this subject have shown that therapeutic doses of 
radioactive iodine are determined by thyroid 
ultrasonography (USG), thyroid scintigraphy and RAIU 
results [32, 33]. However, there is no consensus on the 
optimal radioactive iodine dose regimen for benign 
thyroid diseases [15]. There are three approaches for 
dose determination.  
1. Dosimetric Approach: Absorbed dose 
Method 
The activity required for radiation dose (MBq) 
that thyroid gland absorbs as gray (Gy) is most 
often calculated by the Marinelli formula [34-40]. 
The desired radiation dose to be absorbed per 
gram of thyroid gland was calculated as 100-200 
Gy for toxic multinomial goiter, 120-400 Gy for 
toxic adenoma, 80 Gy for upper gastrointestinal 
tract and 70 Gy for goiter below 70 g [35, 41]. 
However, Graves' disease can range up to 
doses of 150-300 Gy/gr [41]. The formulation is 
based on the size of the thyroid gland. The 
chance of cure increases by this method as I-
131 is applied in proportion to the size of the 
gland [29, 32, 33]. To find the volume of the 
thyroid gland, the volume of both lobes are 
calculated separately and than summed up. 
Isthmus and pyramidal lobe are not considered 
in the calculation, so there is an average ± 15% 
error magrin [38, 42].  
In patients with toxic nodule, the volume of the 
functional nodule is determined by USG. 
However, the presence of cystic and / or necrotic 
component of the nodule makes it difficult to 
calculate the volume of the functioning tissue in 
the nodule. The fact that the thyroid gland is 
generally heterogeneous makes it difficult to 
determine the correct dose. Technetium thyroid 
uptake (TcTUs) study can be used to calculate 
the size of autonomic thyroid tissue under TSH 
suppression to exclude it [37-39, 41, 42]. Among 
these, Emrich is the most preferred formula  
[39, 43]. 
2. Dose Given Per Gram Thyroid (µCi/g) 
Method 
It is the method by which the treatment dose is 
determined by using estimated tissue weight and 
RAIU values calculated by USG and 
scintigraphy. Calculation is done with this 
formula: 
Dose (mCi): Estimated weight of autonomic 
function (gr) x 80-200 (µCi/gr) 
24. hour RAIU(%) x 10 
3. Fixed dose Application (Most Common) 
It is the treatment approach based on the 
administration of a similar dose of radioiodine in 
certain clinical categories. It is an easier and 
more effective application than dose calculation 
techniques [39-41, 43, 44]. Starting from 3-5 
mCi, up to 10-15 mC in Graves, higher doses of 
10 mCi to 30 mCi in toxic nodular and 
multinodular goiter can be administered [45].  
Whichever technique is used, outcome is the same: 
As the dose increases, the patient becomes 
hypothyroid sooner, as the dose decreases, the patient 
stays in the hyperthyroid state for a longer time and the 
recurrence rate increases [45].  
Side Effects 
After radioactive iodine treatment for benign thyroid 
diseases, early side effects such as sensitivity on 
thyroid gland, swelling in salivary glands, and nausea 
can be seen. Sensitivity and swelling in the thyroid 
gland respond to nonsteroidal antiinflammatory agents. 
After treatment, hyperthyroidism can be exacerbated, 
called thyroid storm. It is rarely seen but can be fatal. 
Tracheal compression is a severe but rare complication 
which is more frequently seen in patients with large 
thyroid gland. Another rare side effect is vocal cord 
paralysis [7, 46]. In the literature a rare case of Graves’ 
disease induced by the destruction of follicular cells by 
I-131 therapy of toxic nodular disease is reported [47]. 
Hypothyroidism can be seen at various frequencies 
after radioactive iodine therapy. The development of 
hypothyroidism following radioiodine therapy is due to 
the effect of radiation on the ability of the follicular cell 
to regenerate hormone production and to decrease the 
follicular cell population. In Graves' disease, hypo- 
thyroidism is a natural consequence of autoimmune 
pathophysiological process. The incidence of early 
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hypothyroidism showes a linear relationship with 
radiation doses. However, the development of late 
hypothyroidism is at a constant rate, not dose 
independent and is associated with the natural course 
of the disease [15]. It can develop in 26% to 43% of 
cases in the first year after treatment. This rate 
increases regularly every year after then. It is not 
possible to predict which patient will develop 
hypothyroidism before treatment. The incidence of 
long-term hypothyroidism is dose-independent [15, 45]. 
When studies conducted by various researchers are 
evaluated together, the efficacy of radioactive iodine 
treatment in solitary toxic nodular goitre was 
determined to be 85-100% and it has been reported 
that hypothyroidism develops by 10-20% after 
treatment. considering the incidence of late recurrence, 
the success of radioactive iodine therapy has been 
reported to be higher in by surgery [41, 47-53]. The 
success rate in toxic multinodular and toxic diffuse 
goiter patients using different dosing protocols were 
reported as 92% [37, 38, 54].  
Whether the dose of radioactive iodine administered 
for the treatment of hyperthyroidism increases the risk 
of developing secondary malignancy or not is still being 
discussed. In the literature, there is no reported case of 
a malignancy with secondary and single doses given 
for the treatment of hyperthyroidism. However, the 
leukemia development was reported at high cumulative 
doses administered at multiple sessions [55-57]. 
Evaluation of Treatment Response 
After treatment, normalization of thyroid function 
and clinical signs occurs within the first 4-8 weeks, 
often improved within 2-6 months. Early hypothyroidism 
can be observed in rare cases, followed by recurrent 
hyperthyroidism. If hyperthyroidism persists after 6 
months, it should be evaluated again for treatment. 
Second dose should be administered on time if 
clinically evidenthyperthyroidism persists. Patient 
should be directed to surgery if hyperthyroidism 
persists despite several treatments [13, 14, 29, 41, 45]. 
Radiation Safety 
The radioactive iodine doses used in benign thyroid 
diseases do not require hospitalization. To reduce the 
radiation dose the patients will be exposed to, 
hydration and frequent urination should be 
recommended. Patients should be informed that 
radiation will exist in sweat, urine and saliva secretions 
for a long time after treatment, they will spread 
radiation to the environment in their surrounding and 
that they should be avoided from pregnant and young 
children in accordance with the period specified in the 
radiation safety guide [11].  
Use of Radioiodine in Childhood Hyperthyroidism 
Graves is the most common cause of 
hyperthyroidism in children as well as in adults. 
Radioiodine therapy is less preferred than other 
methods because of radiation exposure and associated 
secondary cancer. However, since there is no proven 
effect, it can be used in the presence of Graves in 
children over five years of age. The risk of developing 
thyroid cancer in children under five years of age 
receiving radioiodine treatment is two times higher than 
that of children receiving five-nine years of age, five 
times higher than children treated at ten to fourteen 
years was reported. Thus, it is wise to avoid radioiodine 
therapy in children under age 5. It can be considered 
for children between the ages of five and fifteen [13]. 
In cases of nodular hyperthyroidism, radioiodine 
therapy may not be appropriate for the treatment of 
toxic nodules in children due to the possibility of cancer 
risk associated with low radiation exposure to the 
normal thyroid gland adjacent to the nodule [58]. 
DISCUSSION 
Radioiodine-131 is used in treatment of benign 
thyroid diseases with hyperthyroidism; Graves disease, 
toxic nodular/multinodular goiter for a long time as well 
as benign euthyroid thyroid diseases; non toxic diffuse 
goiter, non toxic adenoma and non toxic multinodular 
goiter. Cost-effectivity, good tolerability, easy 
application, safety and efficacy are advantages of this 
treatment. The effectiveness of radioiodine therapy is 
related to various factors; the size of the thyroid gland, 
RAIU value, dose and metabolism of I-131. Fixed dose 
application is the most commonly prefered method 
among all treatment approaches due to its easier and 
more effective application than dose calculation 
techniques. It is based on the administration of a 
similar dose of radioiodine in certain clinical categories. 
For Graves’ disease it starts from 3-5 mCi, up to 10-15 
mCi, for toxic nodular/multinodular goiter higher doses 
are required as from 10 mCi to 30 mCi can be 
administered. Possible complications are tolerable. 
Multidisciplinary approach is very important in the 
treatment of benign thyroid disease and improves 
treatment effectiveness.  
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CONCLUSION 
Radioiodine therapy is widely used in treatment of 
hyperfunctioning thyroid diseases and should be 
considered as a safe and costeffective alternative to 
surgery and medical therapies. 
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